SLC40A1 (Ferroportin) variants and mutations
SLC40A1 (also known as Ferroportin) is a human protein-coding gene encoding a ferroportin protein. It exports iron from enterocytes, macrophages, and hepatocytes into the circulation and is directly inhibited by hepcidin. Pathogenic variants cause ferroportin disease or hepcidin-resistant iron overload, depending on whether they impair export or hepcidin regulation. This analysis covers 946 SLC40A1 variants and mutations. Of these, 95% have computational variant effect predictions. Disease context includes hemochromatosis type 4, infantile epileptic encephalopathy, and restless legs syndrome. Example SLC40A1 variants include T2S, R3G, and R3K.
Variant analysis overview
- Gene: SLC40A1
- Protein: Ferroportin
- UniProt accession: Q9NP59
- Organism: Homo sapiens
- Variants analyzed: 946
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 566 unspecified-consequence records; 188 missense variants; 164 synonymous variants; 15 frameshift variants; 2 in-frame deletions; 6 stop-gained variants; 3 splice-region variants; 1 in-frame insertions; 1 substitution
- Prediction scores: 902 variants have prediction scores (95% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: hemochromatosis type 4, infantile epileptic encephalopathy, restless legs syndrome, hereditary hemochromatosis, aceruloplasminemia, neurodegenerative disease, hereditary disease, hemochromatosis type 1, hepatocellular carcinoma, Alzheimer disease, Miyoshi myopathy, lung carcinoma.
Protein structure and variant hotspots
- Protein features: 12 transmembrane segments; 4 binding sites; 1 post-translational modification sites.
- Structural context: 497 variants have structural context.
- PTM context: 3 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable SLC40A1 variants
Examples include T2S, R3G, R3K, A4T, A4V, G5E, D6N, N8S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- T2S (p.Thr2Ser), rs1424413416, ClinGen CA349990183, ClinVar RCV001337456, TOPMed rs1424413416, REVEL 0.25, CADD 15.80, Uncertain significance, Hemochromatosis type 4
- R3G (p.Arg3Gly), Ensembl rs2105637231
- R3K (p.Arg3Lys), TOPMed rs1227165313, gnomAD rs1227165313, REVEL 0.22, CADD 13.80
- A4T (p.Ala4Thr), TOPMed rs1297054517, gnomAD rs1297054517, REVEL 0.30, CADD 11.70
- A4V (p.Ala4Val), TOPMed rs2031425068, REVEL 0.19, CADD 19.00
- G5E (p.Gly5Glu), NCI-TCGA Cosmic COSV9965, Variant assessed as somatic; moderate impact.
- D6N (p.Asp6Asn), ExAC rs771526028, gnomAD rs771526028, REVEL 0.19, CADD 17.90
- N8S (p.Asn8Ser), gnomAD rs1250643463, REVEL 0.23, CADD 8.59
- R9C (p.Arg9Cys), ExAC rs747421463, TOPMed rs747421463, gnomAD rs747421463, REVEL 0.36, CADD 24.60, Uncertain significance
- R9G (p.Arg9Gly), rs747421463, ClinGen CA2024342, ClinVar RCV002716579, ExAC rs747421463, REVEL 0.27, CADD 23.50, Uncertain significance, Hemochromatosis type 4
- R9H (p.Arg9His), TOPMed rs1291651243, gnomAD rs1291651243, REVEL 0.25, CADD 17.90
- Q10R (p.Gln10Arg), ExAC rs773694230, gnomAD rs773694230, REVEL 0.22, CADD 1.21
- R11G (p.Arg11Gly), TOPMed rs944629352, gnomAD rs944629352
- R11K (p.Arg11Lys), TOPMed rs1167750579, gnomAD rs1167750579, REVEL 0.28, CADD 15.20
- G12V (p.Gly12Val), TOPMed rs2031423070, MetaLR 0.87, MetaSVM 0.87
- C13* (p.Cys13Ter), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; high impact.
- C13W (p.Cys13Trp), Ensembl rs1574248991, MetaLR 0.81, MetaSVM 0.49, Likely benign
- S16C (p.Ser16Cys), gnomAD rs1180451928, REVEL 0.71, CADD 26.90
- L17V (p.Leu17Val), Ensembl rs2031400807
- A18S (p.Ala18Ser), Ensembl rs2031400711, MetaLR 0.82, MetaSVM 0.26
- D19G (p.Asp19Gly), gnomAD rs1043875318, REVEL 0.31, CADD 21.20
- D19N (p.Asp19Asn), gnomAD rs1421189425, REVEL 0.24, CADD 18.00
- Y20H (p.Tyr20His), TOPMed rs1379715048, gnomAD rs1379715048, REVEL 0.82, CADD 31.00
- T22I (p.Thr22Ile), Ensembl rs1241539432, MetaLR 0.86, MetaSVM 0.80
- S23Y (p.Ser23Tyr), gnomAD rs1251688835, REVEL 0.83, CADD 32.00
- A24T (p.Ala24Thr), ExAC rs768832055, TOPMed rs768832055, gnomAD rs768832055, REVEL 0.57, CADD 22.50
- A24V (p.Ala24Val), rs749417873, ClinGen CA2024318, ClinVar RCV002223417, ExAC rs749417873, REVEL 0.75, CADD 29.80, Uncertain significance, not provided
- F26L (p.Phe26Leu), NCI-TCGA TCGA novel, MetaLR 0.83, MetaSVM 0.71, Variant assessed as somatic; moderate impact.
- L27F (p.Leu27Phe), ExAC rs780093738, TOPMed rs780093738, gnomAD rs780093738, REVEL 0.48, CADD 24.50
- L30P (p.Leu30Pro), TOPMed rs1266820154
- G31D (p.Gly31Asp), rs1488625305, ClinGen CA349989982, ClinVar RCV001139636, ClinVar RCV004783903, REVEL 0.71, CADD 25.20, Uncertain significance, not provided; Hemochromatosis type 4
- H32R (p.His32Arg), NCI-TCGA TCGA novel, REVEL 0.84, CADD 24.70, Variant assessed as somatic; moderate impact.
- L34F (p.Leu34Phe), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact.
- T36A (p.Thr36Ala), gnomAD rs1236809082, REVEL 0.70, CADD 24.70
- D39N (p.Asp39Asn), TOPMed rs2031255838, REVEL 0.85, CADD 27.50
- R40Q (p.Arg40Gln), rs746832217, ClinGen CA2024293, ClinVar RCV001919692, ClinVar RCV004671532, REVEL 0.86, CADD 29.50, Uncertain significance, Inborn genetic diseases; Hemochromatosis type 4
- R40W (p.Arg40Trp), Ensembl rs80248011, REVEL 0.96, CADD 33.00, Uncertain significance, Inborn genetic diseases
- M41I (p.Met41Ile), ExAC rs758193749, TOPMed rs758193749, gnomAD rs758193749, REVEL 0.85, CADD 26.20, Uncertain significance, Hemochromatosis type 4
- A45E (p.Ala45Glu), rs752405201, ClinGen CA349989873, ClinVar RCV001420117, ExAC rs752405201, AlphaMissense 1.00, MetaLR 0.91, Uncertain significance, Hemochromatosis type 4
- A45V (p.Ala45Val), rs752405201, NCI-TCGA Cosmic COSV5372, ExAC rs752405201, gnomAD rs752405201, REVEL 0.76, AlphaMissense 1.00, Uncertain significance
- V46A (p.Val46Ala), ExAC rs754563739, gnomAD rs754563739, REVEL 0.83, CADD 27.20
- S47F (p.Ser47Phe), rs2105631748, ClinGen CA349989861, ClinVar RCV001420116, Ensembl rs2105631748, AlphaMissense 0.97, MetaLR 0.77, Uncertain significance, Hemochromatosis type 4
- S47P (p.Ser47Pro), rs1574245587, ClinGen CA349989865, ClinVar RCV001027529, Ensembl rs1574245587, AlphaMissense 0.84, MetaLR 0.82, Uncertain significance, not provided
- V48L (p.Val48Leu), gnomAD rs1246828353
- F49L (p.Phe49Leu), rs2468780568, ClinGen CA349989854, ClinVar RCV003505737, REVEL 0.89, CADD 25.70, Uncertain significance, Hemochromatosis type 4
- L53I (p.Leu53Ile), ESP rs140258599, TOPMed rs140258599
- Y54C (p.Tyr54Cys), ExAC rs756895365, TOPMed rs756895365, gnomAD rs756895365, REVEL 0.92, CADD 31.00
- Y54F (p.Tyr54Phe), ExAC rs756895365, TOPMed rs756895365, gnomAD rs756895365, REVEL 0.74, CADD 27.20
- G55E (p.Gly55Glu), NCI-TCGA Cosmic COSV5372, REVEL 0.84, CADD 24.70, Variant assessed as somatic; moderate impact.
- N56S (p.Asn56Ser), ExAC rs762368407, gnomAD rs762368407, MetaLR 0.79, MetaSVM 0.52
- S57R (p.Ser57Arg), TOPMed rs1262427670, gnomAD rs1262427670, REVEL 0.78, CADD 24.70
- L59R (p.Leu59Arg), TOPMed rs935580650
- L60W (p.Leu60Trp), TOPMed rs1356919926, gnomAD rs1356919926, REVEL 0.89, CADD 29.20
- T61I (p.Thr61Ile), gnomAD rs1293705628, REVEL 0.81, CADD 28.90
- V63A (p.Val63Ala), rs2105631709, ClinGen CA349989761, ClinVar RCV001420124, Ensembl rs2105631709, AlphaMissense 0.57, MetaLR 0.91, Likely pathogenic, Hemochromatosis type 4
- V63I (p.Val63Ile), rs2468780515, ClinGen CA349989765, ClinVar RCV003320965, ClinVar RCV005102891, Uncertain significance, not specified; Hemochromatosis type 4
- Y64C (p.Tyr64Cys), TOPMed rs1344593826
- Y64H (p.Tyr64His), rs1285653301, ClinGen CA349989758, ClinVar RCV001228946, Ensembl rs1285653301, AlphaMissense 0.97, MetaLR 0.65, Uncertain significance, Hemochromatosis type 4
- Y64N (p.Tyr64Asn), rs1285653301, UniProt VAR 030057, Ensembl rs1285653301, AlphaMissense 0.97, MetaLR 0.65, Pathogenic, in HFE4
- G65R (p.Gly65Arg), Ensembl rs766231231, REVEL 0.94, CADD 27.40
- V67M (p.Val67Met), gnomAD rs760601296, REVEL 0.77, CADD 25.20
- A69S (p.Ala69Ser), rs2468780495, ClinGen CA349989728, ClinVar RCV003368967, Uncertain significance, Inborn genetic diseases
- S71A (p.Ser71Ala), gnomAD rs1403643921
- S71C (p.Ser71Cys), rs1040988213, ClinGen CA62904039, ClinVar RCV002638225, TOPMed rs1040988213, REVEL 0.69, AlphaMissense 0.32, Uncertain significance, Hemochromatosis type 4
- S71F (p.Ser71Phe), rs1040988213, ClinGen CA349989714, ClinVar RCV001420125, TOPMed rs1040988213, AlphaMissense 0.32, MetaLR 0.66, Likely pathogenic, Hemochromatosis type 4
- S71P (p.Ser71Pro), gnomAD rs1403643921, REVEL 0.79, CADD 29.10
- V72F (p.Val72Phe), ESP rs374617058, TOPMed rs374617058, gnomAD rs374617058
- V72L (p.Val72Leu), ESP rs374617058, TOPMed rs374617058, gnomAD rs374617058, REVEL 0.64, CADD 23.70
- L75P (p.Leu75Pro), Ensembl rs925577572
- G76E (p.Gly76Glu), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact.
- A77D (p.Ala77Asp), rs28939076, ClinGen CA117517, ClinVar RCV000005744, UniProt VAR 022594, AlphaMissense 0.99, MetaLR 0.65, Pathogenic, Hemochromatosis type 4
- A77G (p.Ala77Gly), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact., in HFE4
- A77T (p.Ala77Thr), Ensembl rs868553007
- I79M (p.Ile79Met), ExAC rs769966493, TOPMed rs769966493, gnomAD rs769966493, REVEL 0.67, CADD 21.30
- I79V (p.Ile79Val), rs2031251997, ClinGen CA349989674, ClinVar RCV001139634, TOPMed rs2031251997, REVEL 0.62, CADD 23.90, Uncertain significance, Inborn genetic diseases; Hemochromatosis type 4
- G80C (p.Gly80Cys), rs978427853, ClinGen CA349989668, ClinVar RCV002293038, ClinVar RCV003097823, AlphaMissense 0.99, MetaLR 0.98, Conflicting interpretations, SLC40A1-related disorder; not provided; Hemochromatosis type 4
- G80S (p.Gly80Ser), rs978427853, ClinGen CA62904035, ClinVar RCV001385870, UniProt VAR 030058, REVEL 0.95, AlphaMissense 0.99, Pathogenic/Likely pathogenic, Hemochromatosis type 4
- G80V (p.Gly80Val), rs104893673, ClinGen CA117527, ClinVar RCV000005750, UniProt VAR 030059, AlphaMissense 1.00, MetaLR 0.98, Pathogenic, Hemochromatosis type 4
- D81E (p.Asp81Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D81H (p.Asp81His), Ensembl rs2031251550
- D81V (p.Asp81Val), Ensembl rs2031251459, MetaLR 0.87, MetaSVM 0.79
- W82G (p.Trp82Gly), gnomAD rs1389213679, REVEL 0.89, CADD 32.00
- V83G (p.Val83Gly), Ensembl rs1574245468, MetaLR 0.92, MetaSVM 1.04
- K85N (p.Lys85Asn), TOPMed rs1476073918, gnomAD rs1476073918, REVEL 0.53, CADD 24.40, Uncertain significance, Inborn genetic diseases
- N86S (p.Asn86Ser), TOPMed rs1428238370, MetaLR 0.51, MetaSVM -0.16
- A87T (p.Ala87Thr), ExAC rs776750415, gnomAD rs776750415, REVEL 0.22, CADD 22.70
- A87V (p.Ala87Val), Ensembl rs772429685, REVEL 0.34, CADD 25.40
- R88G (p.Arg88Gly), rs387907374, ClinGen CA215957, NCI-TCGA Cosmic COSV9965, ClinVar RCV000049565, REVEL 0.95, CADD 28.90, Pathogenic/Likely pathogenic, Hemochromatosis type 4
- R88T (p.Arg88Thr), rs1057521155, ClinGen CA16604003, ClinVar RCV000435183, ClinVar RCV003505111, AlphaMissense 1.00, MetaLR 0.93, Pathogenic/Likely pathogenic, not provided; Hemochromatosis type 4
- L89F (p.Leu89Phe), TOPMed rs1387864275, REVEL 0.63, CADD 24.40
- L89R (p.Leu89Arg), gnomAD rs1489844745, REVEL 0.76, CADD 27.50
- V91A (p.Val91Ala), Ensembl rs2031178159, REVEL 0.71, CADD 23.80
- Q93H (p.Gln93His), NCI-TCGA Cosmic COSV5372, REVEL 0.53, CADD 16.90, Variant assessed as somatic; moderate impact.
- S95L (p.Ser95Leu), NCI-TCGA Cosmic COSV5372, REVEL 0.60, CADD 30.00, Variant assessed as somatic; moderate impact.
- V97A (p.Val97Ala), Ensembl rs1259020211, MetaLR 0.41, MetaSVM -0.36
- V97L (p.Val97Leu), gnomAD rs886055361, REVEL 0.18, CADD 18.20, Uncertain significance
- V97M (p.Val97Met), rs886055361, ClinGen CA10611803, ClinVar RCV000396650, gnomAD rs886055361, REVEL 0.51, CADD 24.10, Uncertain significance, Hemochromatosis type 4
- V98A (p.Val98Ala), gnomAD rs1371577452, REVEL 0.42, CADD 23.20
- V98L (p.Val98Leu), rs1429796784, ClinGen CA349989539, ClinVar RCV002926673, TOPMed rs1429796784, AlphaMissense 0.18, MetaLR 0.25, Uncertain significance, Hemochromatosis type 4
- I104T (p.Ile104Thr), Ensembl rs540742265
- I104V (p.Ile104Val), TOPMed rs2031177115, MetaLR 0.44, MetaSVM -0.29
- L110R (p.Leu110Arg), Ensembl rs905096892
- L110V (p.Leu110Val), TOPMed rs1407674110, gnomAD rs1407674110, REVEL 0.75, CADD 24.50
- M111I (p.Met111Ile), gnomAD rs1176988923, REVEL 0.73, CADD 25.60
- M111V (p.Met111Val), NCI-TCGA TCGA novel, MetaLR 0.73, MetaSVM 0.31, Variant assessed as somatic; moderate impact.
- M112I (p.Met112Ile), gnomAD rs1413696546, NCI-TCGA Cosmic COSV5372, REVEL 0.23, CADD 19.30, Variant assessed as somatic; moderate impact.
- V113A (p.Val113Ala), TOPMed rs1400078305, gnomAD rs1400078305, REVEL 0.73, CADD 27.00, Uncertain significance, SLC40A1-related disorder
- V113G (p.Val113Gly), TOPMed rs1400078305, gnomAD rs1400078305, MetaLR 0.89, MetaSVM 0.97, Uncertain significance
- F114S (p.Phe114Ser), TOPMed rs2031175912, REVEL 0.93, CADD 29.90
- L115* (p.Leu115Ter), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; high impact.
- L115F (p.Leu115Phe), Ensembl rs1574243906
- L115V (p.Leu115Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- H116Q (p.His116Gln), 1000Genomes rs535193686, ExAC rs535193686, TOPMed rs535193686, gnomAD rs535193686, REVEL 0.39, CADD 23.00
- H116R (p.His116Arg), gnomAD rs2031175738, REVEL 0.36, CADD 23.20
- H118R (p.His118Arg), ExAC rs755671419, TOPMed rs755671419, gnomAD rs755671419, REVEL 0.29, CADD 15.40, Uncertain significance, Inborn genetic diseases
- L120F (p.Leu120Phe), ExAC rs745342705, gnomAD rs745342705, REVEL 0.63, CADD 26.90
- T122I (p.Thr122Ile), rs2031175179, ClinGen CA349989374, ClinVar RCV001046385, Ensembl rs2031175179, AlphaMissense 0.09, MetaLR 0.76, Uncertain significance, Hemochromatosis type 4
- M123I (p.Met123Ile), Ensembl rs1322381738, REVEL 0.21, CADD 15.10
- M123L (p.Met123Leu), ESP rs370057411, ExAC rs370057411, TOPMed rs370057411, gnomAD rs370057411, REVEL 0.18, CADD 17.40
- M123T (p.Met123Thr), TOPMed rs1387171420, MetaLR 0.44, MetaSVM -0.55
- M123V (p.Met123Val), ESP rs370057411, ExAC rs370057411, TOPMed rs370057411, gnomAD rs370057411, REVEL 0.20, CADD 17.50
- H125N (p.His125Asn), rs568086191, ClinGen CA62903804, ClinVar RCV001211436, ClinVar RCV005732309, REVEL 0.19, CADD 18.10, Uncertain significance, Inborn genetic diseases; Hemochromatosis type 4
- H125Q (p.His125Gln), TOPMed rs1052452054, gnomAD rs1052452054, REVEL 0.20, CADD 17.10
- H125R (p.His125Arg), ExAC rs753119904, gnomAD rs753119904, REVEL 0.47, CADD 23.20, Uncertain significance, Inborn genetic diseases
- H125Y (p.His125Tyr), rs568086191, ClinGen CA2024246, ClinVar RCV003486252, ClinVar RCV005495566, REVEL 0.30, CADD 22.30, Uncertain significance, Inborn genetic diseases; Hemochromatosis type 4
- G126E (p.Gly126Glu), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact.
- G126R (p.Gly126Arg), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact.
- G126V (p.Gly126Val), gnomAD rs2031174315, REVEL 0.86, CADD 29.60
- W127* (p.Trp127Ter), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; high impact.
- V128F (p.Val128Phe), NCI-TCGA Cosmic COSV5372, Variant assessed as somatic; moderate impact.
- V128I (p.Val128Ile), ExAC rs765633684, TOPMed rs765633684, gnomAD rs765633684, REVEL 0.21, CADD 16.10
- L129F (p.Leu129Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- L129H (p.Leu129His), TOPMed rs2031173886, gnomAD rs2031173886, REVEL 0.86, CADD 27.10
- T130I (p.Thr130Ile), rs915023560, ClinGen CA62903706, ClinVar RCV001756869, gnomAD rs915023560, REVEL 0.61, CADD 25.20, Uncertain significance, not provided
- Y133C (p.Tyr133Cys), TOPMed rs1262972709, gnomAD rs1262972709, REVEL 0.93, CADD 31.00
- I139V (p.Ile139Val), Ensembl rs1574243127, MetaLR 0.56, MetaSVM -0.09
- A140T (p.Ala140Thr), TOPMed rs2031136661, REVEL 0.83, CADD 24.40
- N141K (p.Asn141Lys), NCI-TCGA TCGA novel, MetaLR 0.28, MetaSVM -0.76, Variant assessed as somatic; moderate impact.
- I142V (p.Ile142Val), TOPMed rs2031136260, gnomAD rs2031136260, REVEL 0.24, CADD 16.90
- A143E (p.Ala143Glu), TOPMed rs956608384, gnomAD rs956608384, REVEL 0.75, CADD 27.40
- N144D (p.Asn144Asp), rs104893662, ClinGen CA349989223, ClinVar RCV001858656, UniProt VAR 030060, REVEL 0.69, AlphaMissense 0.30, Pathogenic, Hemochromatosis type 4
- N144H (p.Asn144His), rs104893662, ClinGen CA117515, ClinVar RCV000005743, UniProt VAR 022595, AlphaMissense 0.30, MetaLR 0.74, Pathogenic, Hemochromatosis type 4
- N144T (p.Asn144Thr), rs1434101655, UniProt VAR 030061, Ensembl rs1434101655, AlphaMissense 0.32, MetaLR 0.83, Pathogenic, in HFE4
- N144Y (p.Asn144Tyr), rs104893662, ClinGen CA10581910, ClinVar RCV000234752, Ensembl rs104893662, AlphaMissense 0.30, MetaLR 0.74, Pathogenic, Hemochromatosis type 4
- A146T (p.Ala146Thr), Ensembl rs1031328628, REVEL 0.92, CADD 26.30
- S147N (p.Ser147Asn), rs987371643, ClinGen CA349989202, ClinVar RCV003271831, AlphaMissense 0.49, MetaLR 0.57, Uncertain significance, Inborn genetic diseases
- S147T (p.Ser147Thr), Ensembl rs987371643, MetaLR 0.57, MetaSVM -0.02
- T148A (p.Thr148Ala), rs2105628182, ClinGen CA349989197, ClinVar RCV001420127, Ensembl rs2105628182, AlphaMissense 0.29, MetaLR 0.54, Likely pathogenic, Hemochromatosis type 4
- T148S (p.Thr148Ser), Ensembl rs2105628180, MetaLR 0.62, MetaSVM -0.06
- T150A (p.Thr150Ala), rs954631081, ClinGen CA62903700, ClinVar RCV003367072, Ensembl rs954631081, REVEL 0.52, CADD 22.50, Uncertain significance, Inborn genetic diseases
- I152F (p.Ile152Phe), gnomAD rs1328696186
- I152V (p.Ile152Val), rs1328696186, gnomAD rs1328696186, REVEL 0.64, CADD 24.90, Variant assessed as somatic; moderate impact.
- I154V (p.Ile154Val), NCI-TCGA Cosmic COSV9965, REVEL 0.69, CADD 24.00, Variant assessed as somatic; moderate impact.
- R156K (p.Arg156Lys), NCI-TCGA Cosmic COSV9965, Ensembl rs2031134539, MetaLR 0.94, MetaSVM 1.06, Variant assessed as somatic; moderate impact.
- D157G (p.Asp157Gly), rs104893663, ClinGen CA117519, ClinVar RCV000005745, UniProt VAR 022596, AlphaMissense 1.00, MetaLR 0.95, Likely pathogenic, Hemochromatosis type 4
- D157N (p.Asp157Asn), Ensembl rs1320278205
- D157V (p.Asp157Val), Ensembl rs104893663, MetaLR 0.95, MetaSVM 1.10, Likely pathogenic, in HFE4
- W158C (p.Trp158Cys), rs1423207026, ClinGen CA349989126, ClinVar RCV000689049, Ensembl rs1423207026, AlphaMissense 1.00, MetaLR 0.95, Pathogenic, Hemochromatosis type 4
- W158G (p.Trp158Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- W158L (p.Trp158Leu), rs387907375, ClinGen CA215960, ClinVar RCV000049566, Ensembl rs387907375, AlphaMissense 0.98, MetaLR 0.91, Uncertain significance, not provided
- I159T (p.Ile159Thr), TOPMed rs1192335273, MetaLR 0.86, MetaSVM 0.80
- I159V (p.Ile159Val), ESP rs375694920, ExAC rs375694920, TOPMed rs375694920, gnomAD rs375694920, REVEL 0.33, CADD 22.10
- V160A (p.Val160Ala), rs1553494286, ClinGen CA349989115, ClinVar RCV000584752, Ensembl rs1553494286, AlphaMissense 0.79, MetaLR 0.90, Pathogenic, Hemochromatosis type 4
- V160F (p.Val160Phe), rs2105628115, ClinGen CA349989117, ClinVar RCV001365008, Ensembl rs2105628115, AlphaMissense 0.78, MetaLR 0.93, Uncertain significance, Hemochromatosis type 4
- V162I (p.Val162Ile), rs2468775907, ClinGen CA349989105, ClinVar RCV003839751, Uncertain significance, Hemochromatosis type 4
- A163G (p.Ala163Gly), ExAC rs780368217, gnomAD rs780368217, REVEL 0.80, CADD 24.90
- G164R (p.Gly164Arg), ExAC rs756389348, gnomAD rs756389348, REVEL 0.84, CADD 27.60, Uncertain significance, Hemochromatosis type 4
- E165D (p.Glu165Asp), NCI-TCGA TCGA novel, MetaLR 0.63, MetaSVM 0.05, Variant assessed as somatic; moderate impact.
- E165G (p.Glu165Gly), rs1426749167, ClinGen CA349989087, ClinVar RCV002774737, TOPMed rs1426749167, REVEL 0.26, CADD 17.20, Uncertain significance, Inborn genetic diseases
- R167K (p.Arg167Lys), rs750595460, ExAC rs750595460, AlphaMissense 0.10, MetaLR 0.69, Variant assessed as somatic; moderate impact.
- K169Q (p.Lys169Gln), ExAC rs767707750, gnomAD rs767707750, REVEL 0.20, CADD 22.20
- N172D (p.Asn172Asp), gnomAD rs1169808129, REVEL 0.30, CADD 18.00
- N172S (p.Asn172Ser), Ensembl rs2105622116, REVEL 0.36, CADD 18.30
- N172N (p.Asn172Asn), gnomAD 2-189565598-A-G, CADD 4.61, SIFT 0.00
- M173T (p.Met173Thr), TOPMed rs2030914831, REVEL 0.92, CADD 25.30
- M173V (p.Met173Val), rs1278518794, ClinGen CA349989023, ClinVar RCV001420119, Ensembl rs1278518794, AlphaMissense 0.40, MetaLR 0.85, Uncertain significance, Hemochromatosis type 4
- N174I (p.Asn174Ile), rs1397119020, UniProt VAR 030062, Ensembl rs1397119020, AlphaMissense 0.90, MetaLR 0.97, Benign, in iron overload
- N174S (p.Asn174Ser), rs1397119020, ClinGen CA349989010, ClinVar RCV001205916, Ensembl rs1397119020, AlphaMissense 0.90, MetaLR 0.97, Uncertain significance, Hemochromatosis type 4
- A175D (p.Ala175Asp), rs1060501101, ClinGen CA16610617, ClinVar RCV000472101, Ensembl rs1060501101, AlphaMissense 0.97, MetaLR 0.94, Conflicting interpretations, Increased circulating ferritin concentration; Hemochromatosis type 4
- A175A (p.Ala175Ala), rs762788153, gnomAD 2-189565589-G-C, CADD 6.68
Public SLC40A1 analysis runs
- SLC40A1 analysis run — SLC40A1 (946 variants) — completed 2026-08-22